Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs by Stark, Christoffer K. -J. et al.
fphar-07-00115 May 2, 2016 Time: 17:49 # 1
ORIGINAL RESEARCH
published: 03 May 2016
doi: 10.3389/fphar.2016.00115
Edited by:
Colin H. Macphee,
GlaxoSmithKline, USA
Reviewed by:
Martin C. Michel,
Boehringer Ingelheim Pharma GmbH
& Co KG, Germany
Tamara Paravicini,
RMIT University, Australia
*Correspondence:
Christoffer K.-J. Stark
christoffer.stark@utu.fi
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 14 October 2015
Accepted: 18 April 2016
Published: 03 May 2016
Citation:
Stark CK-J, Tarkia M, Kentala R,
Malmberg M, Vähäsilta T, Savo M,
Hynninen V-V, Helenius M,
Ruohonen S, Jalkanen J, Taimen P,
Alastalo T-P, Saraste A, Knuuti J,
Savunen T and Koskenvuo J (2016)
Systemic Dosing of Thymosin Beta 4
before and after Ischemia Does Not
Attenuate Global Myocardial
Ischemia-Reperfusion Injury in Pigs.
Front. Pharmacol. 7:115.
doi: 10.3389/fphar.2016.00115
Systemic Dosing of Thymosin Beta 4
before and after Ischemia Does Not
Attenuate Global Myocardial
Ischemia-Reperfusion Injury in Pigs
Christoffer K.-J. Stark1,2*, Miikka Tarkia3, Rasmus Kentala1, Markus Malmberg2,
Tommi Vähäsilta1,2, Matti Savo1, Ville-Veikko Hynninen4, Mikko Helenius5,
Saku Ruohonen1, Juho Jalkanen6, Pekka Taimen7, Tero-Pekka Alastalo5, Antti Saraste3,
Juhani Knuuti3, Timo Savunen1 and Juha Koskenvuo1
1 Research Center of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland, 2 Heart Center,
Turku University Hospital and University of Turku, Turku, Finland, 3 Turku PET Centre, Turku University Hospital and University
of Turku, Turku, Finland, 4 Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku
University Hospital, Turku, Finland, 5 Children’s Hospital, Pediatric Cardiology, Helsinki University Hospital, Helsinki, Finland,
6 Department of Vascular Surgery, Turku University Hospital and University of Turku, Turku, Finland, 7 Department of
Pathology, Turku University Hospital and University of Turku, Turku, Finland
The use of cardiopulmonary bypass (CPB) and aortic cross-clamping causes myocardial
ischemia-reperfusion injury (I-RI) and can lead to reduced postoperative cardiac
function. We investigated whether this injury could be attenuated by thymosin beta
4 (TB4), a peptide which has showed cardioprotective effects. Pigs received either
TB4 or vehicle and underwent CPB and aortic cross-clamping for 60 min with cold
intermittent blood-cardioplegia and were then followed for 30 h. Myocardial function and
blood flow was studied by cardiac magnetic resonance and PET imaging. Tissue and
plasma samples were analyzed to determine the amount of cardiomyocyte necrosis and
apoptosis as well as pharmacokinetics of the peptide. In vitro studies were performed
to assess its influence on blood coagulation and vasomotor tone. Serum levels of the
peptide were increased after administration compared to control samples. TB4 did
not decrease the amount of cell death. Cardiac function and global myocardial blood
flow was similar between the study groups. At high doses a vasoconstrictor effect
on mesentery arteries and a vasodilator effect on coronary arteries was observed and
blood clot firmness was reduced when tested in the presence of an antiplatelet agent.
Despite promising results in previous trials the cardioprotective effect of TB4 was not
demonstrated in this model for global myocardial I-RI.
Keywords: thymosin beta 4, cardiopulmonary bypass, ischemia-reperfusion injury, cardioprotection, coagulation,
vasoconstriction
INTRODUCTION
Cardiopulmonary bypass (CPB) assisted open-heart surgery allows the surgeon to work in a quiet
and bloodless operating field and is mandatory in many routine types of cardiac surgery. During
CPB the heart is stopped and isolated from the blood circulation while protected from ischemia
with cardioplegic solution. After ischemia, the return of myocardial blood flow (MBF) leads to
reperfusion injury causing further damage to the heart. Ischemia-reperfusion injury (I-RI) can
be identified by biomarkers for cardiomyocyte death, reduced cardiac function and the incidence
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of arrhythmias (Anselmi et al., 2004; Nesher et al., 2008;
Hausenloy et al., 2012). Disrupted microvascular blood flow is
usually seen after revascularization procedures but is also present
after protected I-RI (Boyle et al., 1996; Verrier and Morgan, 1998;
Wong et al., 2013). Extracorporeal circulation causes a systemic
inflammatory response that can lead to organ dysfunction and
hemodynamic instability (Hausenloy et al., 2013). Different
approaches to minimize the effects of myocardial I-RI have been
studied extensively, there is, however, little agreement regarding
the most optimal cardioprotective strategy in heart surgery.
Especially high-risk patients could benefit from more effective
methods attenuating I-RI (Bolli et al., 2004).
Thymosin beta 4 (TB4) is a naturally occurring g-actin
sequestering peptide that is expressed in most cell-types and
is especially abundant in inflammatory cells and thrombocytes.
Some reports have showed an important role for the peptide
during cardiovascular organ development although there is
some debate regarding this argument. In adulthood the effects
are thought to be related to tissue homeostasis and repair
(Smart et al., 2010; Banerjee et al., 2012; Goldstein et al., 2012;
Rossdeutsch et al., 2012). At sites of tissue injury the peptide is
released in high quantities and bound to fibrin and fibrinogen
potentially increasing its bio-availability (Goldstein et al., 2012).
TB4 has previously proved its remarkable therapeutic potential
in several studies using rodent models for myocardial injury and
is thought to aid in both protecting and repairing the heart.
During global myocardial I-RI the peptides anti-inflammatory
and cell-survival promoting properties could be valuable (Bock-
Marquette et al., 2004; Sosne et al., 2010; Stark et al., 2012; Bollini
et al., 2015).
We wanted to test the cardioprotective effect of TB4 in a
clinically relevant surgical model for cardiac I-RI in the subacute
phase and also investigate some of its effects on tissue responses
related to injury. Pigs underwent CPB and cardioplegic heart
arrest for 60 min and were followed for 30 h. TB4 or vehicle was
administered before ischemia and after reperfusion of the heart.
The cardioprotective effects of peptide were analyzed by cardiac
magnetic resonance (CMR) and 15O-water positron emission
tomography (PET) imaging as they are well validated in assessing
myocardial function, viability and blood flow (Viswamitra et al.,
2004; Iida et al., 2012). Biochemical and histological analyses
were performed for pharmacokinetic studies of TB4 and to
determine the amount of cardiomyocyte apoptosis and necrosis.
The knowledge of the peptides’ effects on blood clotting and
arterial contraction is of importance in any surgical model
with regard to risk for bleeding and thrombosis but also when
considering TB4 treatment in thromboembolic conditions such
as myocardial infarction or when planning direct intracoronary
delivery. Therefore we also investigated the peptides influence on
vasomotor tone and on blood coagulation in vitro.
MATERIALS AND METHODS
Anesthesia, Surgery, and Monitoring
Ten landrace pigs weighing 29–43 kg were operated on and
divided into a TB4 treatment group (n = 6) and a control group
(n= 4). All animal experiments were approved by the Laboratory
Animal Care & Use Committee of the State Provincial Office of
Southern Finland.
The pigs were pre-anesthetized with an intramuscular
injection of 100 mg xylazin (Rompun vet, Bayer Animal
Health GmbH, Leverkusen, Germany) and 25 mg midazolam
(Midazolam Hameln, Hameln pharmaceuticals GmbH, Hameln,
Germany). A peripheral ear vein was cannulated and the animals
were medicated with 20 mg boluses of propofol (PropofolLipuro,
B. Braun Melsungen AG, Melsungen, Germany) and 150 µg
phentanyl (Fentanyl-Hameln, Hameln pharmaceuticals GmbH,
Hameln, Germany) and were then intubated and connected
to a respirator (Dräger Oxylog 3000, Drägerwerk AG, Lübeck,
Germany). The respiratory rate was set to 18–22 times/min with
a tidal volume of 8–10 ml/kg using 40% oxygen. Blood gases
were monitored to ensure adequate ventilation (i-STAT, Abbott
Laboratories, Abbott Park, IL, USA). Anesthesia was maintained
with a continuous infusion of propofol 15–30 mg/kg/h, phentanyl
1.5 µg/kg/h and midazolam 100 µg/kg/h. Preoperatively and
every 8 h thereafter the animals received antibiotic prophylaxis
(Cefuroxime 750 mg, Orion Pharma, Espoo, Finland). Before
the heart was cannulated 10000 IU of heparin (Heparin, LEO
Pharma, Ballerup, Denmark) was given as a bolus and the dose
was repeated every 30 min during extracorporeal circulation.
Finally the heparin was neutralized by administering 14000
IU of protamine sulphate (Protamin, LEO Pharma, Ballerup,
Denmark). TB4 (supplied by RegeneRx Biopharmaceuticals Inc,
Rockville, MD, USA) was suspended in sterile water to a
concentration of 4 mg/ml (0.82 mM) and administered 6 mg/kg
through a 15 min intravenous infusion 30 min before the start of
the operation and 6 h later.
The right external jugular vein was cannulated for invasive
central venous pressure monitoring and drug administration.
The femoral artery was cannulated for blood pressure monitoring
and blood sampling. Invasive hemodynamic parameters, ECG
and oxygen saturation were monitored throughout the study
(DatexOhmeda S5, GE Healthcare Finland Oy, Helsinki,
Finland). A percutaneous cystostomy was performed for urine
output monitoring.
Since pigs lack blood groups, a blood donor littermate was
used to prime the perfusion lines of the heart–lung machine. The
donors underwent the same anesthetic protocol and their blood
was drained after heparin administration from the right external
jugular vein via a central venous catheter into the reservoir of the
heart–lung machine.
The pigs were placed in a left lateral decubitus position and
the chest was shaved and disinfected. The animals were draped
and a thoracotomy was performed in the fourth intercostal space
on the right. A rib retractor was used to gain access to the
heart. The lung was displaced and the pericardium opened. Purse
string sutures were placed on the ascending aorta and on the
right auricle for cannulation. The aorta was cannulated with a
pediatric 14 F cannula and the right auricle with a sequential
24/28 F cannula (Medtronic, Minneapolis, MN, USA). A 5 F
cannula was placed at the root of the aorta for cardioplegia
infusion and venting of the heart. Custom-made perfusion lines
were connected between the animal and a pediatric membrane
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oxygenator (Dideco 905 Eos, Dideco, Mirandola, Italy) and
perfusion was initiated. The aorta was cross-clamped and 500 ml
of cold (10◦C) Modified St Thomas Hospital No II cardioplegia
was administered with blood in a 4:1 ratio via the ascending aorta.
A second dose of cardioplegia was given after 30 min. During
perfusion the animals were kept normothermic (36–38◦C) and
the mean arterial pressure was kept at 50–60 mm Hg. Blood
lactate levels were monitored to ensure adequate perfusion. After
60 min the aortic cross-clamp was removed and the heart was
defibrillated as necessary. Some animals required re-clamping
of the aorta with a short cardioplegic arrest due to persistent
ventricular fibrillation. For rhythm disorders 100–150 mg of
lidocaine (Lidocain, Orion Pharmaceuticals, Espoo, Finland)
and 150–225 mg of amiodarone (Cordarone, Sanofi, Helsinki,
Finland) was administered as needed. The heart was vented and
the animals were allowed to wean from CPB until the heart
had recovered and was generating pulsatile flow. Boluses (5 mg)
of ephedrine (Efedrin, Stragen Nordic, Hilleroed, Denmark)
and infusion (80–160 µg/h) of norepinephrine (Noradrenalin
Hospira, Hospira UK Limited, Warwickshire, UK) was used as
needed for postoperative hemodynamic support. After weaning,
the animals were decannulated. A chest tube was left in the
right pleural cavity and connected to negative pressure. The
thoracotomy wound was closed in three layers. The wound
was infiltrated with 50 mg of bupivacaine (Bicain, Orion
Pharmaceuticals, Espoo, Finland) for post-operative analgesia.
20 mg of enoxaparin (Klexane, Sanofi, Helsinki, Finland) was
given for thrombosis prophylaxis 1 and 12 h after the operation.
The animals were kept on mechanical ventilation for the
complete duration of the experiment. Hemodynamic parameters
were continuously monitored and regular blood samples were
drawn for hemoglobin, blood glucose, and pH measurements.
Cardiac troponin T (cTnT) release was measured from plasma
samples at baseline, 6 and 24 h post-reperfusion by electro-
chemiluminescence immunoassay (Elecsys R©Troponin T high
sensitive, Roche Diagnostics Ltd.) performed by the Hospital
District of Southwest Finland laboratory services. The animals
were finally sacrificed by an intravenous injection of potassium
chloride.
Thymosin Beta 4 EIA
Serial serum samples were collected from two animals in both
groups for pharmacokinetic studies of TB4 by EIA. The serum
was prepared and analyzed as parallel samples according to the
manufacturers’ manual (Thymosin β4 EIA Kit, Immundiagnostik
AG, Bensheim, Germany). A coefficient of variation (calculated
as: sample SD/sample mean) of less than 50% between parallel
samples was accepted for final analysis.
Artery Wire Myography
Eighteen representative segments of small mesentery arteries and
coronary arteries (250–350 µm in diameter) from 4 blood-donor
pigs were studied by wire myography for contractile responses
to TB4 in vitro. Samples were excised rapidly and placed in
ice-cold oxygenated Krebs solution. The composition of the
Krebs solution was as follows (in mM): 119 NaCl, 4.7 KCl, 25
NaHCO3, 1.2 NaH2PO4, 2.5 CaCl2, 1.2 MgSO4, and 5.5 glucose.
Arterial rings (2 mm in length) were mounted using 40 µm wires
in a microvessel myograph (Danish Myograph Technologies,
Aarhus, Denmark) for isometric tension recordings. After
mounting, vessels were equilibrated, normalized and contracted
repeatedly with 62 mM potassium chloride until maximal
and reproducible contractions were obtained. To examine the
contracting effects of TB4, dose-response curves to TB4 (10-
8-10-2 M) were constructed and compared to KCl-induced
contraction. Relaxation was studied in thromboxane (TXA2)
precontracted arterial rings. The precontraction was adjusted
to 20–40% of the reference contraction to 62 mM KCl, which
after cumulative concentrations of TB4 was added to the organ
bath. To evaluate the role of NO on the effects of TB4 induced
vasodilation, experiments were repeated in arteries incubated
with L-NNA, a NO synthase inhibitor (100 µM, 30 min). Data
were collected and analyzed using Powerlab and Chart5 softwares
(ADI Instruments, Colorado Springs, CO, USA).
Thromboelastometry Analysis
Rotem R©thromboelastometry (Tem Innovations GmbH, Basel,
Switzerland) analysis was performed in vitro on blood samples
from three blood-donor animals. TB4 was added to citrated
whole blood to achieve two different concentrations (0.1 mM and
1 mM) and incubated at room temperature for 1 h. Untreated
blood samples served as controls. The samples were analyzed
and three parameters were drawn from the results at 60 min:
Maximum clot firmness (stability of the blood clot), clotting
time (time to clot formation), and maximum lysis of the blood
clot. Assays used were EXTEM, INTEM, and FIBTEM. EXTEM
measures the activity of the extrinsic pathway with tissue factor
activation and INTEM of the intrinsic pathway with contact
activation. FIBTEM is used for the assessment of fibrinogen status
by complete platelet inhibition.
Tissue Sample Harvesting and Apoptosis
Detection
Transmural tissue samples from the left and right ventricles were
collected and fixed in formalin. Hematoxylin and eosin staining
was performed for general histological analysis. Cardiomyocyte
apoptosis was determined by terminal transferase nick end-
labeling assay (TUNEL) as previously described (Gavrieli et al.,
1992; Saraste et al., 1997). Positive apoptotic nuclei were counted
over an ocular grid and presented as a percentage of total
cardiomyocyte number in 10 randomly selected microscopic
visual high power (×40) fields by an investigator blinded to group
assignments.
Cardiac Positron Emission Tomography
The pigs underwent cardiac PET scans 25–26 h post-reperfusion
to determine MBF during rest and adenosine stress. PET studies
were performed with ECAT EXACT HR+ scanner (Siemens-
CTI, Knoxville, TN, USA). Myocardial perfusion was evaluated
by PET with 15O-radiolabeled water (808 ± 129 MBq) both at
rest and during intravenous adenosine stress (200 µg/kg/min).
The acquisition frames were as follows: 14 × 5 s, 3 × 10 s,
3 × 20 s, and 4 × 30 s (total duration 4 min 40 s). The
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acquired PET data were reconstructed in 2D mode with an
iterative reconstruction algorithm OSEM using six iteration and
16 subsets in the reconstruction. The transaxial field of view
(35 cm) was reconstructed in a 128 × 128 matrix, yielding a
pixel size of 2.57 mm × 2.57 mm. The measurements were
corrected for scatter, random counts, and dead time. The device
produces 63 axial planes with a slice thickness of 2.43 mm. Global
myocardial perfusion (ml/g/min) was measured using Carimas 2
software (Turku PET Centre, Turku, Finland1).
Cardiac Magnetic Resonance Imaging
Four animals in each group underwent cardiac magnetic
resonance imaging (MRI) 27–30 h post-reperfusion. MRI study
was performed at 1.5 T system (Philips GyroscanIntera Nova
Dual MR, Philips Medical Systems, Best, The Netherlands) with
a phased-array torso coil and a vector cardiographic method
for ECG-gating. All acquisitions were obtained during short
breath hold periods. Each MRI study consisted of cine imaging
of both ventricles for volumetrics and wall motion at rest. Late
enhancement (LE) imaging was applied for scar assessment. MRI
analysis was performed as showed in our previous studies and
an experienced reader, blinded to therapy, analyzed all MRI
exams (Koskenvuo et al., 2007; Mäki et al., 2012). bTFE pulse
sequences were used with the following parameters: retrospective
gating, repetition time/echo time (TR/TE) 3.4/1.2 ms, flip
angle 60, FOV 320–360 mm, acquisition matrix 192 × 256,
reconstruction matrix 256 × 256, rFOV 100%, 30 phases/cardiac
cycle, slice thickness 6.0 mm, and gap 0 mm. A phase-
sensitive inversion recovery T1–TFE pulse sequence was applied
for LE imaging 10 min after injecting gadoterate meglumine
(Dotarem 279.3 mg/mL, Guerbet, Roissy CdG, France) with a
dose 0.3 mmol/kg. The following imaging parameters were used:
prospective gating, TR/TE 4.0/1.2 ms, flip angle 15◦, acquisition
matrix 168 × 256, reconstruction matrix 256 × 256, FOV 320–
360 mm, rFOV 100%, 8–15 slices/breath hold, slice thickness
6 mm, and gap 0 mm. TI was optimized individually using a TI-
scout sequence. The whole LV was covered by LE images at SA
orientation.
Statistical Analysis
Statistical power was calculated with an estimation of a 10%
increase in LVEF with TB4 treatment (alpha 0.05). A power value
of 0.8 gave a sample size of 4–6/group. Data is presented as
mean ± SD or mean ± SEM for myography results. Paired and
1http://www.turkupetcentre.fi/carimas
unpaired t-tests were used for single comparative analysis. Two-
way ANOVA and Tukey’s multiple comparisons test was used for
multiple comparative analysis. A p-value of less than 0.05 was
considered significant in all analyses.
RESULTS
In the TB4 treatment group two animals did not complete the
follow-up period. One pig died shortly after weaning from CPB
due to bradycardia and the other one 20 h after reperfusion due
to circulatory failure. Four animals in each group completed the
study and underwent all planned analyses.
Preoperative and perioperative variables were similar
(Table 1). The use of inotrope and vasopressor agents in the
immediate post-operative period did not differ between the
study groups. All animals received norepinephrine infusions for
short periods of time and small doses of ephedrine. Two animals
in each group required amiodarone and lidocaine therapy for
persistent ventricular fibrillation, the dosage was, however, equal
between the groups. Three animals in both groups required
re-clamping of the aorta and a short cardioplegic re-arrest
due to inability to terminate ventricular fibrillation. The total
aortic cross-clamp times did, however, remain similar between
the study groups. Blood pressure and heart rate values were
consistent throughout the follow-up period. No direct effect
of TB4 treatment was observed on these parameters (Table 2).
Analyzed blood samples showed no signs of hemolysis.
EIA analysis showed increased serum concentrations of TB4
after each dosage (Figure 1). The peak concentration occurred
15 min after the first dose (0.96 µM) and a second peak was
observed at the start of reperfusion (1.5 µM) approximately
3 h after the first dose. An increase, although smaller than in
the treated animals, of endogenous TB4 serum concentration
could be seen in control animals immediately after reperfusion
(0.49 µM). One hour after the second dose the serum
concentration of TB4 was again elevated (1.25 µM), while it
remained low in control samples.
In artery wire myography TB4 showed concentration-
responsive vasoconstriction of mesenteric arteries. At
concentrations of 0.1–1 mM the contractile response was
15–30% of that of maximum potassium chloride stimulation
(Figure 2A). Similarly, TB4 showed modest endothelium-
dependent relaxation in the porcine coronary arteries. The
relaxing effect was abolished by a nitric oxide synthase inhibitor
(L-NNA; Figure 2B). TB4 did not, however, induce vasodilatation
TABLE 1 | Perioperative variables of the operated animals (mean ± SD, range min–max).
Control (n = 4) Thymosin beta 4 (n = 4) P-value
Weight (kg) 31.8 ± 1.9 (30.0− 34.3) 34.4 ± 6.3 (29.1− 43.0) 0.46
Procedure length (min) 192 ± 49 (165− 265) 196 ± 31 (155− 225) 0.91
Perfusion time (min) 106 ± 14 (95− 125) 107 ± 5 (100− 112) 0.82
Aortic cross-clamp time (min) 63.5 ± 2.9 (60.0− 67.0) 61 ± 0.8 (60.0− 62.0) 0.15
Priming volume (ml) 1300 ± 258 (1000− 1600) 1400 ± 163 (1200− 1600) 0.54
Cardioplegia (ml) 631 ± 47 (600− 700) 575 ± 50 (500− 600) 0.15
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TABLE 2 | Hemodynamics of the operated animals.
Heart rate (1/min) Control (n = 4) Thymosin beta 4 (n = 4) P-value
Baseline 103 ± 15 (82− 113) 95 ± 7 (86− 101) 0.31
30 min 124 ± 22 (92− 139) 114 ± 29 (76− 145) 0.59
6 h 128 ± 19 (102− 149) 127 ± 38 (82− 174) 0.96
12 h 131 ± 19 (107− 154) 137 ± 35 (102− 180) 0.78
24 h 122 ± 1 (121− 123) 129 ± 19 (112− 151) 0.54
MAP (mm Hg)
Baseline 66 ± 10 (57− 81) 54 ± 7 (47− 64) 0.10
CPB 56 ± 9 (51− 69) 54 ± 6 (48− 61) 0.69
30 min 63 ± 14(43− 76) 59 ± 8 (48− 66) 0.60
6 h 66 ± 14 (54− 86) 60 ± 10 (47− 68) 0.47
12 h 61 ± 11 (44− 70) 59 ± 9 (48− 69) 0.87
24 h 61 ± 16 (40− 80) 57 ± 11 (42− 66) 0.71
MAP, mean arterial pressure; CPB, cardiopulmonary bypass. Times are post-reperfusion (mean ± SD, range min–max).
FIGURE 1 | Individual serum concentrations of thymosin beta 4 and
mean concentrations in two control (dotted line) and two treated
animals (black line). Thymosin beta 4 was administered intravenously
(6 mg/kg) at 0 min and at 360 min (arrowheads). Bar indicates ischemic
period.
in the mesenteric arteries, nor did it induce vasoconstriction in
the coronary arteries.
The addition of TB4 to whole blood did not have an effect
on blood clotting time or maximal blood clot fibrinolysis at
concentrations used here. The clot firmness was, however,
significantly reduced in the FIBTEM analysis, which measures
clot firmness in the absence of functioning platelets, when
comparing 1–0.1 mM and 0 mM concentrations (27.7 ± 4.2 mm
versus 37.3± 5.9 mm versus 40.6± 9.0 mm, p< 0.05; Figure 3).
General histology showed normal tissue architecture with very
little inflammatory cell infiltration. The extent of myocardial cell
death did not differ between TB4 treated and control animals.
TUNEL analysis showed a similar rate of apoptotic cells in
both left (0.71 ± 0.2% versus 0.41 ± 0.30%, p = 0.17) and
right (0.63 ± 0.24% versus 0.94 ± 0.33%, p = 0.20) ventricles
(Figure 4A). All animals had normal baseline cTnT values
(<50 ng/l). The differences in cTnT plasma concentrations at six
(1100 ± 1053 ng/l versus 437 ± 291 ng/l, p = 0.27) and 24 h
(349 ± 114 ng/l versus 305 ± 75 ng/l, p = 0.55) post-reperfusion
did not reach statistical significance (Figure 4B).
Cardiac [15O]H2O PET studies were carried out 25 h
(range 25–26) post-reperfusion to determine global MBF. Blood
flow during rest was equal between control and TB4 group
(2.01 ± 0.91 ml/g/min versus 1.92 ± 0.38 ml/g/min, p = 0.86).
The values were also corrected for individual and group mean
blood pressure and pulse rate products but the differences
remained insignificant. Coronary flow reserve calculated from
flow during adenosine stress and resting flow values were close
to 1 in both groups (1.15 ± 0.28 versus 0.97 ± 0.35, p = 0.45).
There was an association between cTnT release at 24 h and MBF
at rest (r = 0.85, p< 0.05; Figure 5).
Cardiac magnetic resonance imaging was performed after 28 h
(range 27–30) of reperfusion. Left ventricle ejection fraction was
slightly higher in the treated animals but the difference remained
statistically insignificant (56.7 ± 7.6% versus 61.9 ± 10.6%,
p = 0.45). LVEDV (62.3 ± 3.7 ml versus 60.1 ± 6.8 ml, p = 0.58)
and LVESV (27.2 ± 6.0 ml versus 23.3 ± 8.7 ml, p = 0.49) did
not differ between the groups (Figure 6). When normalized for
body-surface area there was a trend for larger chamber volumes
in control animals (LVEDV/BSA 40.8 ± 2.1 ml/m2 versus
36.7 ± 3.7 ml/m2, p = 0.10 and LVESV/BSA 17.7 ± 3.6 ml/m2
versus 14.0 ± 4.3 ml/m2, p = 0.23). One animal in the TB4
group had mild tricuspid valve regurgitation. In the other subjects
there were no valvular abnormalities. No uptake of gadolinium
contrast was observed on late-enhancement scans in any of the
animals.
DISCUSSION
Thymosin beta 4 is normally found in the cytosol and also in the
nucleus of cells but lacks a signal sequence for exocytosis. It is
unclear whether the high concentrations found in extracellular
fluids, is due to active secretion of the peptide or secondary to
degranulation of inflammatory cells or cell membrane rupture
(Watts et al., 1990; Huff et al., 2001). TB4 is water soluble and
rapidly internalized by endothelial cells in vitro where it binds
to actin and participates in the dynamics of the cytoskeleton
(Cierniewski et al., 2012). At very high concentrations there
is also some binding to f-actin, although this interaction is
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FIGURE 2 | The contractile effects of TB4 on small mesentery arteries (A) and the effects of TB4 on coronary relaxation with TB4 alone and with nitric
oxide synthase inhibitor, L-NNA (B) on arteries from four animals (mean ± SEM).
FIGURE 3 | Maximum blood clot firmness in blood samples from three
animals treated with different concentrations of TB4. EXTEM measures
activity of the extrinsic and INTEM of the intrinsic pathway. FIBTEM is used for
the assessment of fibrinogen status in the absence of platelets (individual
values + mean).
poorly understood (Carlier et al., 1996). Several studies have
showed that intracellular TB4 increases ILK and PI3-K mediated
phosphorylation of Akt which is considered responsible for many
of the peptides’ cardioprotective effects (Bock-Marquette et al.,
2004; Fan et al., 2009; Goldstein et al., 2012). It is reported
that binding of TB4 to extracellular ATP synthase increases ATP
synthesis while ATP hydrolysis is blocked. The local increase
in ATP is linked to P2X4 mediated cell migration but signaling
through other purinergic receptors is also possible (Freeman
et al., 2011).
As the functions of TB4 are thought to be related to tissue
homeostasis and repair after injury we wanted to test the direct
vasomotor effect of the peptide in an in vitro setting. When
using physiological concentrations of TB4 we did not observe
any influence on vasoconstriction or vasodilation but when the
concentration was adjusted to the 0.1–1.0 mM range, we saw an
increase in vasomotor tone in mesentery arteries and a weak NO-
mediated relaxation effect on coronary arteries. Pig coronaries
mainly express β-adrenergic receptors while mesentery vessels
express both α- and β-adrenergic receptors and this could partly
explain the differences in vasomotor behavior of the two vessel
types (Duncker et al., 2012). Vascular smooth muscle tone is
regulated by intracellular Ca2+ and mediated by several cell
surface receptors (Wilson et al., 2005). A previous report showed
an increase in intracellular Ca2+ after treatment with TB4 but
this was not confirmed in a more recent study (Wilson et al.,
2005; Cierniewski et al., 2012). The PI3K/Akt pathway has been
suggested as a regulator of calcium-dependent vasoconstriction,
while pathways for Ca2+-independent vasoconstriction is related
to ILK-mediated phosphorylation of Myosin II (Wilson et al.,
2005; Huang et al., 2006; Sinagra et al., 2013). Purinergic signaling
through P2 receptors is associated with vasomotor responses and
is regulated either in the endothelium or by sympathetic nerve
stimulation in the vessel wall (Burnstock, 2008). One possible
explanation for the differences seen for coronary and mesentery
artery responses could be related to ATP and a differential
expression of vasodilator P2Y and vasoconstrictor P2X receptors
within the tested arteries. We did, however, not test the responses
under the influence of selective purinergic receptor antagonists.
No previous data exists on TB4-mediated vasomotor activity and
we can only speculate whether our findings have any clinical
significance as plasma levels are normally much lower compared
to concentrations tested here. Platelets, however, contain up to
0.5 mM of TB4 and at sites of blood clot formation or after
pharmacological delivery of TB4, local concentrations could
increase sufficiently to cause a vasomotor response mediated by
known or still undiscovered targets of TB4 (Kaur et al., 2010).
It is documented that TB4 covalently binds to fibrin and
fibrinogen by factor XIIIa and that his interaction inhibits platelet
aggregation and adhesion at concentrations higher than 0.5 µM
(Makogonenk et al., 2004; Kaur and Mutus, 2012). Based on the
findings in our vasomotor experiment, we investigated whether
even higher concentrations of TB4 had an influence on blood
coagulation as assessed by thromboelastometry. We observed
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FIGURE 4 | Percentage of TUNEL-positive cells (A) in left and right ventricle tissue samples (n = 3 + 4) 30 h post-reperfusion and plasma
concentrations of cTnT (B) 6 and 24 h post-reperfusion (n = 4 + 4; individual values + mean).
FIGURE 5 | Global myocardial blood flow (A) and coronary flow reserve (B) assessed with cardiac [15O]H2O positron emission tomography 25 h
post-reperfusion (n = 4 + 4). Correlation between myocardial blood flow at rest and cTnT in plasma samples (C) (individual values + mean).
FIGURE 6 | LVEF (A), LVEDV (B), and LVESV (C) assessed by cardiac magnetic resonance imaging 28 h post-reperfusion (n = 4 + 4; individual
values + mean).
a decrease in maximal blood clot firmness with increasing
concentrations from 0.1–1.0 mM when platelets were inhibited
by a potent anti-platelet agent. This method is used to assess
fibrinogen status in whole blood and could indicate that the
fibrinogen–TB4 interaction has a negative effect on blood clot
stability and might be relevant in surgical situations where the
patient is also receiving anti-platelet medication. No effect on
blood clotting time or fibrinolysis was observed.
The preferred dosing range of TB4 seems to be 2–12 mg/kg
both when using single and repeated strategies. The most
commonly used dosage of TB4 in animal studies so far is
∼6 mg/kg, as this dose has showed good therapeutic effect
without signs of adverse reactions either in animal or human
studies (Ruff et al., 2010; Stark et al., 2012; Morris et al., 2014).
We wanted to condition the heart before the operation and also
affect the immediate post-operative reperfusion period and gave
the animals two doses of TB4. Under physiological conditions,
concentrations of the peptide in plasma and serum is reported
to be approximately 0.005–0.01 µM (Kaur et al., 2010; Ruff
et al., 2010). In patients with active rheumatoid arthritis or severe
coronary artery disease undergoing PCI endogenous serum levels
of TB4 have been found to range from 0.1 µM up to 600 µM
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(Biçer et al., 2011; Song et al., 2012). In our study, the levels
increased to above normal physiological levels in treated animals
and remained low in controls. There is little knowledge regarding
tissue pharmacokinetics of TB4 and the optimal therapeutic
levels in blood or tissue. Maximal tissue concentrations in heart
have been found at 2 h after intraperitoneal administration of
the peptide, so we considered this time point to be suitable
for the first infusion (Mora et al., 1997). In a previous study
using a similar model for I-R injury, the rate of cardiomyocyte
death was showed to increase already within the first hours of
reperfusion (Malmberg et al., 2006). Therefore, we decided to give
the second dose early during reperfusion in order to target cell-
death signaling at this stage. Cardioprotection in rodents has been
observed after administration both locally and systemically. We
administered the peptide through intravenous infusions as this is
also clinically the most feasible method (Bao et al., 2013). Tissue
concentrations of TB4 were not measured, so we cannot say
whether significant amounts of the peptide retained in the heart,
nor did we assess whether the TB4 dose used caused a significant
biological reaction, such as an increase in phosphorylated Akt.
It is therefore possible that our dosing strategy was insufficient
to cause a cellular response. In a previous mouse model the
total amount of TB4 recovered from the heart was very small
compared to the dose originally administered (Mora et al.,
1997). In our opinion, optimal cardioprotective tissue and blood
concentrations should be determined in order to decide whether
intravenous administration in its current form and if dosages
used in studies on rodents are adequate also in larger mammals.
We failed to show any significant cardioprotective effect of
TB4 in this animal model for global myocardial I-RI. Although
previous data is encouraging, to date only a few studies have
been performed using large animal models. Overexpression of
TB4 by viral vector gene transfer proved beneficial in a pig model
for heterotopic heart transplantation (Postrach et al., 2014). In a
balloon-occlusion model using pigs there was a decrease in infarct
size, inflammation and apoptosis after 1 h of unprotected local
ischemia and 24 h of reperfusion when TB4 was infused at the
site of injury at the end of the ischemic period (Hinkel et al.,
2008). In our study, the setting was different and mimics the
conditions during normal CPB assisted open-heart surgery where
cardioplegia protects the heart from ischemic insult, placing more
emphasis on cardiac injury during reperfusion. The model is also
different in that it does not cause myocardial infarction but global
and diffuse heart injury.
Macroscopic post-mortem analysis of the two animals that
died did not reveal any obvious cause of death. Bradycardia is
a known problem after CPB and could be related to damage to
the sinoatrial node or the conduction system. The pathogenesis
of circulatory failure is usually multifactorial and was here
probably associated with CPB induced systemic inflammation
and myocardial damage. This study was, however, not designed
to investigate survival so we cannot conclude whether TB4
treatment influenced mortality. Our results show that there
was substantial cardiomyocyte injury following the procedure as
demonstrated by the increase in post-operative cTnT levels and
the rate of apoptosis. TB4 did, however, not influence the rate of
myocardial cell death. The lack of Gadolinium-contrast uptake
on late-enhancement scans showed that there were no larger
areas of non-viable myocardium, indicating that the cell necrosis
caused in this model is diffuse and not detectible by conventional
MRI imaging. Reduction in cardiac function after I-R injury is
either permanent or transient. Necrosis and apoptosis leads to
a reduced number of working cardiomyocytes, hence impairing
cardiac work more or less permanently. Cardiac stunning is a
phenomenon seen after different types of cardiac insult and is
recognized as a transient decrease in cardiac contractility while
blood-flow of the myocardium remains unchanged (Kloner and
Jennings, 2001a,b). In this study, left ventricle EF was reduced in
both study groups with a slight, although insignificant benefit for
TB4 treated animals. There was also a trend for larger diastolic
and systolic dimensions of the left ventricle in control animals.
We did not record baseline values with either PET or cMRI.
Based on previous experience with pigs of similar size and origin
we know that baseline LVEF is 64–74% and that global I-RI
causes an 8–15% reduction in left ventricle EF in early reperfusion
(Vähäsilta et al., 2001; Malmberg et al., 2006, 2011). The complete
duration of this stunning effect is unknown but is thought
to begin resolving within the first 2 days after I-RI. Impaired
cardiac contractility in the immediate postoperative period can;
however, be troublesome and cause substantial morbidity to
patients (Kloner and Jennings, 2001a,b)
A no-reflow phenomenon has been associated with cardiac
I-RI and we wanted to determine global myocardial perfusion
and possible effects by TB4 treatment in the subacute phase
of I-RI. Coronary flow reserve was low in both study groups.
This can be related to increased basal blood flow or inability
of the coronaries to respond to adenosine stimulation. At the
time of imaging the animals’ heart rates were high and blood
pressure values quite low. Adenosine stress might have interfered
with the autoregulation of the coronary circulation leading to
inability to increase MBF despite maximal vasodilatation. Some
correlation between cTnT levels in plasma and MBF during rest
was observed which could indicate an association between the
extent of cell injury and hyperemia. In preclinical models using
unprotected local myocardial I-RI injury, blood flow is decreased
early after reperfusion and remains low during the first 24 h
(McFalls et al., 1995). In studies with protected global I-RI,
MBF has been showed to increase immediately after ischemia,
then decrease within the first hours of reperfusion and later
rise to normal or even higher levels. In some situations this
hyperdynamic blood flow is still observed several days after
surgery, the clinical significance of this is, however, unclear
(Vähäsilta et al., 2001; Aburawi et al., 2009). Measuring MBF at
an earlier time point might have showed signs of malperfusion
and could have highlighted some differences between the
groups.
The prolonged time on mechanical ventilation and the use of
inotropic agents in the postoperative period are factors that could
influence several outcome measurements in this study. The use of
these drugs was often necessary in order to successfully wean the
animals from CPB as it also is in clinical situations. Keeping the
animals sedated for the whole follow-up period was considered
to be appropriate as recovery from anesthesia and re-intubation
for imaging procedures would have caused additional stress to
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the animals increasing the possibility for complications such as
hypoxemia and arrhythmias.
We here partly reached our conclusions regarding functional
outcome based on historical data from similar experiments
performed by our group. It is possible that the current model
didn’t cause a sufficient therapeutic window for TB4 treatment
as no baseline imaging procedures were performed or sham-
operated animals used. Post hoc sample size calculations for a
power of 0.8 with the EF values obtained from the study (56.7
vs. 61.9, SD 7.6) gave a sample size of 34/group. The post hoc
calculated power in our study was 0.12. Sample size based on
EF was originally calculated with a 10% (EF 55% versus 65%)
improvement and a variance of 6 SD. The observed difference
was therefore 4.8% lower and the variance 1.6 SD higher than
calculated. Since this is the first study of its kind, hypothetical
effect sizes were generated based on results from similar IR-I
studies with pigs and animal models with myocardial infarction
and TB4 treatment. A 5% difference in EF during the post-
operative period is in our opinion not clinically significant
compared to 10% with the model used. For a post hoc power of
0.8, an increase in EF of 15% would have been necessary with the
current sample size and observed variance. Based on the small
difference in EF between the groups, we consider this to be a
true negative (neutral) observation. Increasing sample size would
probably not have influenced effects size although it would have
provided more power.
CONCLUSION
With regard to the limiting factors addressed above, we conclude
that TB4 treatment was not beneficial in this model for
global myocardial I-RI assessed by several different markers for
cardiac damage. Although promising in studies conducted on
rodents, the cardioprotective potential of TB4 has not been well
established in large animal models or clinical trials. Previous
studies performed on pigs have all relied on local myocardial
delivery or cardiac overexpression of the peptide. Further studies
are therefore needed to clarify whether systemic administration
also is an option in other species and also to determine sufficient
dosing strategies. The peptides cellular functions have been
investigated quite extensively but more clinically oriented studies
are needed in order to translate its therapeutic potential from
bench to bedside. This study offers novel information on some
potentially significant biological actions of the peptide related to
blood coagulation and vasomotor function and can serve as a
reference in planning future studies related to cardioprotection
and TB4.
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